ArticleCancer cell2015
Something in the air: hyperoxic conditioning of the tumor microenvironment for enhanced immunotherapy.
Article in Cancer cell, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Cold and hot tumors: immunological determinants, cancer-immunity cycle dysregulation, and nanotechnology-driven therapeutic approaches.Molecular biomedicine · 2026Review
- Tumour- and Non-Tumour-Associated Factors That Modulate Response to PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer.Cancers · 2025Review
- Oxygen-carrying nanoemulsions and respiratory hyperoxia eliminate tumor hypoxia-induced immunosuppression.JCI insight · 2025Article
- Acute remote ischemic conditioning enhances (CD3+)- but not (FoxP3+)-T-cell invasion in the tumor center and increases IL 17 and TNF-alpha expression in a murine melanoma model.Frontiers in immunology · 2024Article
- Review
- A signature of six-hypoxia-related genes to evaluate the tumor immune microenvironment and predict prognosis in gastric cancer.BMC medical genomics · 2022Article
- Acute vs. chronic vs. intermittent hypoxia in breast Cancer: a review on its application in in vitro research.Molecular biology reports · 2022Review
- Circadian rhythms and cancers: the intrinsic links and therapeutic potentials.Journal of hematology & oncology · 2022Review
- The Effect of Hypoxia and Hypoxia-Associated Pathways in the Regulation of Antitumor Response: Friends or Foes?Frontiers in immunology · 2022Review
- 8DEstablishment and validation of a hypoxia-related signature predicting prognosis in hepatocellular carcinoma.BMC gastroenterology · 2021Article
- Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy.Journal of experimental & clinical cancer research : CR · 2021Review
- Article
- Transcutaneous Carbon Dioxide Decreases Immunosuppressive Factors in Squamous Cell Carcinoma In Vivo.BioMed research international · 2021Article
- Shedding Light on the Role of Neurotransmitters in the Microenvironment of Pancreatic Cancer.Frontiers in cell and developmental biology · 2021Review
- CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers.Frontiers in immunology · 2020Review
- Review
- GαThe Journal of experimental medicine · 2019Article
- Synchronous delivery of oxygen and photosensitizer for alleviation of hypoxia tumor microenvironment and dramatically enhanced photodynamic therapy.Drug delivery · 2018Article
- Targeting adenosine for cancer immunotherapy.Journal for immunotherapy of cancer · 2018Review
- Prolonged activation of cAMP signaling leads to endothelial barrier disruption via transcriptional repression of RRAS.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2018Article
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
Abstract
Recent clinical trials in cancer therapy have demonstrated unprecedented responses through blockade of CTLA-4 and PD-1 immune checkpoint pathways. In a provocative recent paper in Science Translational Medicine, Hatfield and colleagues demonstrate the ability of supplemental oxygen to act as a novel immune checkpoint inhibitor by disrupting the hypoxia-adenosine-A2aR pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.